Printable View
Britain's Oxford Biomedica said on Friday it had signed a new three-year agreement to manufacture AstraZeneca's Covid-19 vaccine beyond 2022.
Oxford Biomedica, whose commitments under a previous deal for AstraZeneca's vaccine will end at the end of 2022, said it expected to record about 30 million pounds ($36.4 million) in revenue from the contract in the current financial year.
Oxford Biomedica has announced a new deal with AstraZeneca Covid, which will see the two companies work together to develop novel treatments for cancer. The agreement was signed by Oxford Biomedica's CEO, Dr. Pieter Cohen, and AstraZeneca Covid's CEO, Dr. Laurent Thiery. Cohen said that the partnership would allow Oxford Biomedica to "address some of the biggest challenges in oncology with world-leading technologies and expertise.